Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Operating Leases (2023 - 2026)

Centessa Pharmaceuticals has reported Operating Leases over the past 3 years, most recently at $7.6 million for Q4 2025.

  • Quarterly Operating Leases fell 8.6% to $7.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.6 million through Dec 2025, down 8.6% year-over-year, with the annual reading at $7.6 million for FY2025, 8.6% down from the prior year.
  • Operating Leases was $7.6 million for Q4 2025 at Centessa Pharmaceuticals, down from $8.4 million in the prior quarter.
  • Over five years, Operating Leases peaked at $9.7 million in Q1 2023 and troughed at $7.6 million in Q4 2025.
  • The 3-year median for Operating Leases is $8.8 million (2023), against an average of $8.8 million.
  • The largest YoY upside for Operating Leases was 0.0% in 2025 against a maximum downside of 8.6% in 2025.
  • A 3-year view of Operating Leases shows it stood at $8.9 million in 2023, then dropped by 6.77% to $8.3 million in 2024, then decreased by 8.6% to $7.6 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Operating Leases are $7.6 million (Q4 2025), $8.4 million (Q3 2025), and $8.6 million (Q2 2025).